https://www.selleckchem.com/products/sbe-b-cd.html
Of 142 patients with GIST receiving ripretinib 150mg QD, 67 underwent IPDE. IPDE provided benefit across all lines of therapy; the median PFS2 was 5.6, 3.3and 4.6 months for patients on second-, third-and ≥fourth-line therapy, respectively. A partial metabolic response after IPDE was demonstrated in 13 of 37 patients with available positron emission tomography scans. TEAEs reported at both doses were similar. Ripretinib IPDE after PD provided continued clinical benefit in advanced GIST across second, third and later lines of therapy wi